Ginkgo Bioworks Holdings, Inc. SEC filings DNA
Ginkgo Bioworks Holdings, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Acquisition or sale of assets
|
Apr 7, 2026 | Apr 3, 2026 |
| 8-K |
Current report
Material agreement
|
Feb 27, 2026 | Feb 26, 2026 |
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| 10-K | Annual report | Feb 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 23, 2025 | Dec 18, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Sep 4, 2025 | Sep 4, 2025 |
| 424B5 | Prospectus supplement | Sep 4, 2025 | — |
| 8-K |
Current report
Other events
|
Aug 29, 2025 | Aug 29, 2025 |
| EFFECT | Filing | Aug 14, 2025 | — |
| CORRESP | Letter to the SEC | Aug 12, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2025 | — |
| S-3 | Shelf registration | Aug 7, 2025 | — |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 21, 2025 | May 19, 2025 |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 12, 2025 |
| S-8 | Employee stock plan registration | Feb 25, 2025 | — |
| 10-K | Annual report | Feb 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2025 | Feb 25, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 12, 2024 | Nov 6, 2024 |
| 25-NSE | Delisting notice | Sep 12, 2024 | — |
| 8-K |
Current report
Listing notice, Other events
|
Sep 4, 2024 | Sep 3, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 19, 2024 | Aug 19, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 15, 2024 | Aug 14, 2024 |
| DEFA14A | Additional proxy material | Aug 12, 2024 | — |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K/A |
Amended current report
Results of operations, Exit or restructuring costs
|
Aug 8, 2024 | May 9, 2024 |
| DEF 14A | Proxy statement | Jul 5, 2024 | Aug 14, 2024 |
| UPLOAD | Letter from the SEC | Jul 5, 2024 | — |
| PRER14A | Filing | Jul 3, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jun 28, 2024 | — |
| PRE 14A | Preliminary proxy statement | Jun 25, 2024 | Aug 14, 2024 |
| 8-K/A |
Amended current report
Exit or restructuring costs
|
Jun 24, 2024 | May 9, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| CORRESP | Letter to the SEC | Jun 13, 2024 | — |
| UPLOAD | Letter from the SEC | May 30, 2024 | — |
| EFFECT | Filing | May 17, 2024 | — |
| 424B3 | Prospectus | May 17, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
May 13, 2024 | May 7, 2024 |
| S-3 | Shelf registration | May 9, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Auditor change
|
Mar 14, 2024 | Mar 8, 2024 |
| S-8 | Employee stock plan registration | Mar 1, 2024 | — |
| 10-K | Annual report | Feb 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 10, 2024 | Jan 10, 2024 |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 27, 2023 | Oct 27, 2023 |
| 8-K |
Current report
Other events
|
Oct 3, 2023 | Oct 3, 2023 |
| EFFECT | Filing | Aug 29, 2023 | — |
| 424B3 | Prospectus | Aug 29, 2023 | — |
| 8-K |
Current report
Other events
|
Aug 29, 2023 | Aug 29, 2023 |
| CORRESP | Letter to the SEC | Aug 25, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2023 | — |
| S-3 | Shelf registration | Aug 23, 2023 | — |
| 8-K |
Current report
Other events
|
Aug 23, 2023 | Aug 23, 2023 |
| 10-Q | Quarterly report | Aug 9, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2023 | Jun 16, 2023 |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DNA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1830214
- Former names
- Soaring Eagle Acquisition Corp. (until Sep 17, 2021); Spinning Eagle Acquisition Corp. (until Jan 4, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.